Isao Yasumatsu

Novel orally bioavailable EZH1/2 dual inhibitors with greater antitumor efficacy than an EZH2 selective inhibitor

Daisuke Honma, Osamu Kanno, Jun Watanabe et al. · Cancer Science · 2017 · 139 citations · Full text

Medicine, Molecular Biology, Oncology +17

Mechanisms of action and resistance in histone methylation-targeted therapy

Makoto Yamagishi, Yuta Kuze, Seiichiro Kobayashi et al. · Nature · 2024 · 104 citations · Full text

Medicine, Molecular Biology, Oncology +16

Discovery and structure-guided fragment-linking of 4-(2,3-dichlorobenzoyl)-1-methyl-pyrrole-2-carboxamide as a pyruvate kinase M2 activator

Yumi Matsui, Isao Yasumatsu, Takashi Asahi et al. · Bioorganic & Medicinal Chemistry · 2017 · 30 citations · Full text

Pharmacy, Biochemistry, Medicinal Chemistry +12

Discovery of Novel Pyrido-pyridazinone Derivatives as FER Tyrosine Kinase Inhibitors with Antitumor Activity

Toru Taniguchi, Hiroaki Inagaki, Daichi Baba et al. · ACS Medicinal Chemistry Letters · 2019 · 27 citations · Full text

Pharmacy, Medicinal Chemistry, Oncology +13

Discovery of DS79932728: A Potent, Orally Available G9a/GLP Inhibitor for Treating β-Thalassemia and Sickle Cell Disease

Katsushi Katayama, Ken J. Ishii, Hideki Terashima et al. · ACS Medicinal Chemistry Letters · 2020 · 27 citations · Full text

Medicine, Genetics, Pharmacology +12